Subcutaneous amivantamab shows shorter administration time and fewer infusion reactions in advanced solid tumors
Could a simple injection replace hours-long cancer infusions?
A phase Ib clinical trial in 158 patients with advanced solid malignancies evaluated subcutaneous amivantamab administration. Compared to hi…
A new injection method for advanced cancer treatment cuts administration time to under 10 minutes and reduces severe side effects compared t…
Amivantamab-lazertinib shows OS benefit over osimertinib in Asian EGFR-mutant NSCLC subset
Combination therapy shows longer survival than standard drug in Asian lung cancer patients
In a subset analysis of an RCT of 629 Asian patients with untreated EGFR-mutant advanced NSCLC, amivantamab-lazertinib prolonged overall sur…
Asian lung cancer patients on a new two-drug combination therapy lived longer than those taking the standard single drug, with a 26% lower r…